Sentences with phrase «effects of the drug include»

The most common side effects of the drug include respiratory infections and constipation, with possible chances of reduced platelet levels and kidney damage.

Additional side effects of the drug include osteoporosis, a condition in which bones become weak and brittle; akathisia, a disorder characterized by the need to be in constant motion, including the head and jaw; bruxism, or teeth grinding; and dryness of the mouth, all of which affect the implant healing process, says Bairam.

In women, the side effects of this drug include acquiring male characteristics such as deepening of voice and masculinization.

Side effects of the drug include sedation, which is usually temporary during the first one to two weeks of medication use and wanes as the patient's body adjusts.

Not exact matches

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

KeyBioscience designed these drugs, which include BP - 089 and KBP - 056, to have the same broad mechanism of action as KBP - 042 but deliver different effects or potency because of changes to their engineering.

In many ways Betel is stricter than a lot of rehabilitation centres; no drugs are allowed, including prescription drugs, if they have a psychoactive effect.

There is enough evidence that antidepressants cause increased risk of suicide and violence for the U.S. Food and Drug Administration and its Canadian counterpart to require that drug companies include a «black box» warning to that effect on their packaDrug Administration and its Canadian counterpart to require that drug companies include a «black box» warning to that effect on their packadrug companies include a «black box» warning to that effect on their packages.

That could have a range of consequences, including effects on blood sugar, regulation of body weight, inflammatory bowel disease, and how drugs and other chemicals are absorbed and metabolized by the body.

«That would depend on a lot of things, including the side effects of the drugs,» says Dr. Barry Starr, a geneticist at Stanford University's Tech Museum of Innovation and who runs its «Ask a Geneticist» column.

A new study in the Australian and New Zealand Journal of Gynaecology confirms what many who have undergone a hospital birth already know: the use of the labor - inducing drug pitocin (synthetic oxytocin) leads to great pain and suffering, including serious adverse, unintended health effects to both mother and infant.

Drugs used in active management have documented risks for the mother, including death, and we do not know the long - term effects of these drugs, which are given at a critical stage of brain development, for the Drugs used in active management have documented risks for the mother, including death, and we do not know the long - term effects of these drugs, which are given at a critical stage of brain development, for the drugs, which are given at a critical stage of brain development, for the baby.

Other common side effects of epidurals include: inability to pass urine (and requirement for a urinary catheter) for up to two - thirds of women; 38 itching of the skin (pruritus) for up to two - thirds of women administered an opiate drug via epidural; 39, 40 shivering for up to one in three women; 41 sedation for around one in five women; 42 and nausea and vomiting for one in 20 women.43

Other side effects of PPI drugs include headache, constipation, vomiting, stomach pain, and rashes.

Dr. Perry's research includes: the effects of prenatal drug exposure on brain development, the neurobiology of human neuropsychiatric disorders, the neurophysiology of traumatic life events, and long - term cognitive, behavioral, emotional, social and physiological effects of neglect and trauma in children, adolescents and adults.

«Baroness Smith of Basildon to move that this House regrets that Her Majesty's Government's plans for the introduction of the draft Misuse of Drugs Act 1971 (Amendment)(No. 2) Order 2014 do not include provisions for a 12 - month review of the impact of the reclassification of khat in view of the highly unusual community focus of its use, for putting a detailed policing strategy in place before a ban takes effect, or for a health strategy to prevent a transfer of addiction to other substances; and do not commit the Department for International Development to do more work with the government of Kenya to alleviate the effect of the reclassification on the Kenyan economy.»

Invited participants include: Senator David Valesky; Assemblyman Mark Gjonaj; Councilman Ritchie Torres; Councilman Andrew Cohen; Public Advocate Letitia James; Deputy Bronx Borough President Aurelia Green; Special Agent in Charge of the U.S. Drug Enforcement Administration, New York Division, James J. Hunt; FBI Assistant Special Agent in Charge, Violent Crimes Division, Michael Osborn; Interim Medical Director of Behavioral Health at HHC, Dr. Charles Barron; NYC DOH Commissioner Mary Basset; NYC DCA Commissioner Julie Menin; President of NYSCOPBA Michael Powers; Representatives from New York, Queens, Kings and Bronx county district attorneys» offices; and parents dealing with the devastating effects of K2.

Topics include the rights of persons with disabilities; the rights and responsibilities of drug users and ethical considerations for dignified addiction treatment; improving maternal and child health through advancements in women's rights; the effects of violence; access to affordable and appropriate health care and treatment; health disparities between different population groups; health during war and conflict; the health of internally displaced persons and refugees; and recognition of social and structural forces that impact the health of individuals and groups.

The U.S. Food and Drug Administration originally approved the drug in 1999, but subsequent case reports of abnormal behavior in adolescents who used the medication led the agency in 2006 to require that all packaging of the drug include a warning label about potential neuropsychiatric side effects, such as hallucinations, delirium, self - harm and even suicDrug Administration originally approved the drug in 1999, but subsequent case reports of abnormal behavior in adolescents who used the medication led the agency in 2006 to require that all packaging of the drug include a warning label about potential neuropsychiatric side effects, such as hallucinations, delirium, self - harm and even suicdrug in 1999, but subsequent case reports of abnormal behavior in adolescents who used the medication led the agency in 2006 to require that all packaging of the drug include a warning label about potential neuropsychiatric side effects, such as hallucinations, delirium, self - harm and even suicdrug include a warning label about potential neuropsychiatric side effects, such as hallucinations, delirium, self - harm and even suicide.

Those suspected of having TB may also be given potent antibiotics as a precaution — drugs that can cause serious side effects, including vomiting, headaches, rash and drug - induced hepatitis (liver inflammation).

31 percent of the pill group experienced side effects from the make - believe drug, including dizziness, restlessness, rashes, headaches, nausea, and 4 cases of nightmares.

The law also calls for a new database that would scan hospital and insurance records for trends in side effects of certain drugs and include data from 25 million patients by 2010.

And one of the main drugs previously used to treat the infectious liver disease was not very effective and had many side effects, including the possibility of transplant rejection.

«Most researchers have relied on cell lines to screen the effect of drugs and other treatments including viruses,» said Dr. Cripe, who also is a professor at The Ohio State University College of Medicine.

Seventy per cent of the websites provided information on the safe usage of prescription medications, including potential side effects or adverse reactions when combined with other drugs.

«Although the effects of the drug were modest, we now know that we can influence the course of the disease, and we expect to build on this success with other drugs, including some already in development,» said senior author, Gary K. Schwartz, MD, professor of medicine and chief of hematology / oncology at NewYork - Presbyterian / Columbia University Medical Center and associate director of its Herbert Irving Comprehensive Cancer Center.

New findings by UH biomedical engineer Chandra Mohan and his team raise hope for a new class of drugs to treat lupus that may not include the long list of adverse risks and side effects often associated with current treatments.

NSAID labels include warnings about potential increases in blood pressure but there is little data on the effects of individual drugs.

New findings by a biomedical engineer and his team at the University of Houston (UH) raise hope for a new class of drugs to treat lupus that may not include the long list of adverse risks and side effects often associated with current treatments for this disease.

These include the family of so - called exercise pills, drugs designed to boost the rate at which bodies burn fat and dissipate the energy as heat — an effect that would provide many of the benefits of regular mild exercise.

Vitamin B6 has been shown to have a small effect on hangover in scientific studies, as have prostaglandin inhibitors, a class of drugs that includes aspirin and ibuprofen; for optimum effectiveness these should be taken while you are drinking, not the next morning, though they can also help the morning after.

The program works by connecting computer - generated drug profiles — including mechanisms of action, clinical efficacy, and side effects — with information about how a molecule may interact with human proteins in specific diseases, such as ovarian cancer.

The drugs also significantly reduced the negative effects of a high - fat diet in mice, including reducing weight gain and, to the researchers» surprise, significantly lowering blood glucose levels and improving responsiveness to insulin.

After hearing about his work, several other companies, including Pfizer, Bayer, and Eli Lily, decided to examine the effects of different genetic variants on the efficacy and safety of drugs they had in development.

But if you knew that the effect of a drug had a lot to do with whether you inherited specific genes from your mother or father, then you could design an experiment that would include parents.

Enquiries often elicit no more than a simple list of drug names and prices, and rarely include much, if any, information about dosage, side effects, or provenance.

But the dogs had no major side effects from taking low doses of the drug, a worry because rapamycin impairs immune system function and could make animals (including people) who take it more vulnerable to infection or cancer.

These drugs may briefly produce side effects that resemble symptoms of psychotic disorders, including changes in perception, delusions, and disorganization of thought processes.

A previous generation of weight loss drugs was linked to this receptor, but because their scope was broader, those products also had dire cardiac side effects including pulmonary hypertension and valve problems.

Whether they will actually lead to a greater incidence of the disease will be complicated by factors including control measures, the availability of drugs, and even other indirect effects of climate change, such as population changes, migration and urbanization.

Some researchers believe that smoking cigarettes and taking recreational drugs like LSD, ecstasy and cannabis, may elevate a user's risk of mental illnesses, including schizophrenia — although it can be difficult to assess whether drug use is a cause or effect.

The Wyss team has unveiled not only a novel design of their «targeted EPO,» but also «targeted interferon alfa,» a cancer drug that can otherwise cause side effects including flu - like symptoms, mood fluctuations, and depression.

Proton pump inhibitors, which include drugs such as Prilosec, Nexium and Prevacid, had the biggest effect: a 45 percent decreased risk of death, compared to patients who did not take antacids.

Numerous medications, including some antihistamines and blood pressure drugs, have been linked to an increased risk of arrhythmias, he says, and people carrying the variant may be more likely to experience that side effect.

Three of the drugs that cut the protein's production, including salbutamol, work by stimulating the b2 - adrenoreceptor — a molecule on some body cells that triggers a variety of effects, including relaxing the airways.

Adverse effects of antipsychotic drugs include extrapyramidal symptoms, such as Parkinsonian involuntary muscle movement.

His research program has provided innovative, seminal discoveries in the field of neuropharmacology, including characterization of the roles of endocannabinoids in the reinforcing effects of abused drugs and, more importantly, the involvement of dysregulated endocannabinoid function in the neuroplastic events that contribute to the pathology of addiction.

We're seeing encouraging results, including the development of more effective drugs with increased efficacy and decreased toxicity, and the ability to better use existing ones, with improved delivery and fewer side effects.

There is increasing evidence in humans and laboratory animals for biologically - based sex differences in every phase of drug addiction including acute reinforcing effects, transition from occasional to compulsive use, withdrawal - associated negative affective states, craving, and relapse.